Add BrightSurf on Google Email

Science News for October 30, 2002


Mild aerobic exercise no protection from osteoporosis

A study found that aerobic exercise did not prevent aging-related bone loss, while higher body fat, especially in the abdomen, was linked to increased bone mineral densities. Muscle strength also played a role in maintaining bone health, contrasting previous studies suggesting aerobics could have a protective effect.

SourceJohns Hopkins Medicine·JournalJournal of Internal Medicine·DateOct 30, 2002

A glimpse of the young Milky Way

Astronomers uncover a star with extremely low element abundance, providing a unique window into the Milky Way's early stages. The discovery challenges current theories and offers hope for finding 'unpolluted' Big Bang material.

SourceESO·JournalNature·DateOct 30, 2002

The Lancet Infectious Diseases (TLID)

Quorum sensing allows bacteria to coordinate unified attacks on hosts through the production of virulence factors. Disrupting quorum sensing might be used to control infection. Other reviews discuss athogenesis of coagulase-negative staphylococci, Q fever in children, and testosterone therapy in HIV wasting syndrome.

SourceThe Lancet_DELETED·JournalThe Lancet Infectious Diseases·DateOct 30, 2002

Databases can heal themselves on-the-fly

A new database technology developed by Dr. Peng Liu can detect single, multiple or simultaneous attacks, isolating malicious transactions while preserving benign ones. The software also repairs the database by containing corrupted data objects and undoing the effects of the attack, allowing for static and on-the-fly repairs.

SourcePenn State·JournalIEEE Transactions on Knowledge and Data Engineering·DateOct 30, 2002

Study shows first progress in heart-failure survival

A recent study from the Framingham Heart Study has shown a small but significant improvement in heart-failure survival rates since the 1990s. This increase is attributed to the widespread adoption of proven-effective medications such as beta-blockers, ACE inhibitors, and aldosterone antagonists. The findings suggest that treating patie...

SourceMayo Clinic·JournalNew England Journal of Medicine·DateOct 30, 2002

The Lancet Oncology (TLO)

Imatinib mesylate has shown significant effectiveness in treating gastrointestinal stromal tumours (GISTs), a previously difficult-to-treat cancer type. The drug's success is attributed to its ability to target KIT tyrosine kinase mutations, which are present in most GISTs.

SourceThe Lancet_DELETED·JournalThe Lancet Oncology·DateOct 30, 2002